Donald TrumpPolitics

Trump Administration Withdraws Heidi Overton’s FDA Nomination Following Bipartisan Senate Opposition

The White House has withdrawn Dr. Heidi Overton’s nomination to lead the Food and Drug Administration after growing opposition from Republican and Democratic senators threatened her chances of confirmation.

The decision came Tuesday evening, just one day before the Senate Health, Education, Labor and Pensions Committee was scheduled to vote on advancing her nomination.

A senior administration official confirmed that Overton lacked sufficient congressional support to move forward, prompting President Trump’s administration to abandon the confirmation effort.

Overton, a physician and deputy director of the White House Domestic Policy Council, was nominated in August to replace former FDA Commissioner Marty Makary, who resigned in May.

Her nomination encountered resistance over several issues, including childhood vaccination policies, abortion medication, flavored vaping products, and questions about her management experience.

Republican Senator Bill Cassidy of Louisiana, who chairs the Senate health committee, previously expressed serious concerns about Overton’s involvement in efforts to revise federal childhood vaccination recommendations.

Cassidy also questioned whether Overton possessed the leadership experience necessary to oversee the FDA, which regulates prescription medications, medical devices, food products, and tobacco products.

However, Cassidy disputed the administration’s decision to withdraw her nomination, arguing that negotiations with senators had created a possible path to confirmation.

The Louisiana Republican said his conversations with Overton had convinced him that she would prioritize scientific evidence and challenge decisions that could endanger public health.

Overton also faced scrutiny over her views on mifepristone, an FDA-approved abortion medication. She previously raised concerns about the drug but acknowledged during her confirmation hearing that it had satisfied the agency’s approval standards.

Anti-abortion organizations pressed the administration to secure stronger commitments regarding federal oversight of abortion medications before moving forward with her confirmation.

Meanwhile, activists opposing Overton’s nomination launched a public campaign criticizing her perceived support for flavored vaping products. Signs targeting the nominee appeared around Capitol Hill in the days leading up to the scheduled vote.

The controversy also exposed disagreements among advocates of HHS Secretary Robert F. Kennedy Jr.’s Make America Healthy Again initiative, with some questioning whether Overton would sufficiently challenge corporate interests.

Administration officials maintained that the FDA needs leadership aligned with Kennedy’s broader health agenda, emphasizing a renewed focus on public health and regulatory priorities.

The agency has operated under acting Commissioner Kyle Diamantas since Makary’s departure, leaving one of the federal government’s most influential regulatory positions without a permanently confirmed leader.

Republican Senator Roger Marshall of Kansas, a physician who recently lost his reelection campaign, has reportedly emerged as a possible replacement candidate.

The administration now faces a limited window to confirm another nominee before Democrats assume control of the Senate in January.

With Overton’s nomination withdrawn, President Trump must decide whether to pursue another confirmation effort or continue relying on acting leadership while the FDA implements the administration’s health policy priorities.

Ad Blocker Detected!

Refresh